| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Over the last 12 months, insiders at Azitra, Inc. have bought $0 and sold $0 worth of Azitra, Inc. stock.
On average, over the past 5 years, insiders at Azitra, Inc. have bought $14.6M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 47,600 shares for transaction amount of $10,034 was made by Staskey Norm (Chief Financial Officer) on 2024‑03‑29.
| 2024-03-29 | Staskey Norm | Chief Financial Officer | 47,600 0.2506% | $0.21 | $10,034 | -87.28% | ||
| 2024-02-13 | Salva Francisco D. | President and CEO | 333,300 2.4975% | $0.30 | $99,990 | -97.42% | ||
| 2024-02-13 | Whitfill Travis | Chief Operating Officer | 15,000 0.1124% | $0.30 | $4,500 | -97.42% | ||
| 2024-02-13 | Staskey Norm | Chief Financial Officer | 3,300 0.0247% | $0.30 | $990 | -97.42% | ||
| 2023-06-21 | Kreis Leslie W. | 10 percent owner | 2.3M – | $3.15 | $7.24M | -73.83% | ||
| 2023-06-21 | Fletcher Aaron G.L. | 10 percent owner | 2.3M – | $3.15 | $7.24M | -73.83% |
| Salva Francisco D. | President and CEO | 338300 2.0532% | $99,798.50 | 1 | 0 | <0.0001% |
| Whitfill Travis | Chief Operating Officer | 334500 2.0302% | $98,677.50 | 1 | 0 | <0.0001% |
| Staskey Norm | Chief Financial Officer | 51100 0.3101% | $15,074.50 | 2 | 0 | <0.0001% |
$296,936 | 37 | -18.12% | $5.4M | |
$1,138,733 | 28 | -4.94% | $3.87M | |
$63,749,694 | 24 | -12.24% | $4.33M | |
$960,082 | 17 | -6.29% | $4.34M | |
$490,284 | 15 | -19.03% | $6.34M | |
$1,556,551 | 15 | -25.43% | $5.74M | |
$139,855 | 11 | -32.84% | $4.05M | |
$309,830 | 10 | -55.78% | $4.12M | |
$100,375 | 8 | -51.85% | $3.68M | |
$159,974 | 7 | -18.60% | $3.57M | |
$214,493 | 7 | -84.84% | $5.84M | |
Azitra, Inc. (AZTR) | $115,514 | 4 | -94.89% | $4.86M |
$76,299 | 4 | 11.60% | $5.6M | |
$726,438 | 4 | -72.85% | $5.74M | |
$37,067 | 3 | -89.81% | $3.53M | |
$1,057,000 | 3 | 5.27% | $5.43M | |
$4,423 | 2 | 3.27% | $5.17M | |
$1,049,630 | 1 | -74.91% | $5.15M | |
$739,010 | 1 | 3.33% | $3.98M |
| Increased Positions | 9 | +112.5% | 382,370 | +149.4% |
| Decreased Positions | 4 | -50% | 105,021 | -41.03% |
| New Positions | 3 | New | 54,644 | New |
| Sold Out Positions | 2 | Sold Out | 47,475 | Sold Out |
| Total Postitions | 13 | +62.5% | 533,292 | +108.36% |
| Virtu Financial Llc | $20.00 | 0.42% | 63,180 | +41,866 | +196.43% | 2024-12-31 |
| National Bank Of Canada /Fi/ | $12.00 | 0.27% | 40,000 | +35,000 | +700% | 2024-12-31 |
| Ubs Group Ag | $12.00 | 0.26% | 38,726 | +38,726 | New | 2024-12-31 |
| Renaissance Technologies Llc | $11.00 | 0.24% | 36,573 | +36,573 | New | 2024-12-31 |
| Geode Capital Management, Llc | $11.00 | 0.23% | 33,948 | +6,848 | +25.27% | 2024-12-31 |
| Xtx Topco Ltd | $6.00 | 0.13% | 19,071 | +19,071 | New | 2024-12-31 |
| Two Sigma Securities, Llc | $4.00 | 0.09% | 12,735 | -21,424 | -62.72% | 2024-12-31 |
| Susquehanna International Group, Llp | $3.00 | 0.07% | 10,902 | +10,902 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $0 | 0.01% | 769 | -30 | -3.75% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | 0% | 39 | 0 | 0% | 2024-12-31 |